Roth Capital reiterated coverage on Champions Oncology with a new price target

3/15/21 10:03:32 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Roth Capital reiterated coverage of Champions Oncology with a rating of Buy and set a new price target of $16.00 from $13.50 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CSBR

Date	Price Target	Rating	Analyst
9/12/2024	$6.00	Hold → Buy	Craig Hallum